MARKET

CERS

CERS

Cerus Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.66
+0.41
+6.56%
Closed 17:58 09/17 EDT
OPEN
6.30
PREV CLOSE
6.25
HIGH
6.68
LOW
6.27
VOLUME
3.10M
TURNOVER
--
52 WEEK HIGH
8.87
52 WEEK LOW
4.670
MARKET CAP
1.14B
P/E (TTM)
-18.3017
1D
5D
1M
3M
1Y
5Y
Cerus Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
CONCORD, Calif., September 15, 2021--Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the 2021 Ca...
Business Wire · 4d ago
Return on Capital Employed Insights for Cerus
After pulling data from Benzinga Pro it seems like during Q2, Cerus's (NASDAQ:CERS) reported sales totaled $31.48 million. Despite a 8.63% in earnings, the company posted a loss of $20.68 million.
Benzinga · 08/20 17:44
Billionaire Ray Dalio Bets on These 3 ‘Strong Buy’ Stocks
When billionaire financier Ray Dalio makes a move, Wall Street pays attention. Dalio, who got his start working on the floor of the New York Stock Exchange trading commodity futures, founded the world’s largest hedge fund, Bridgewater Associates, in 1975. ...
TipRanks · 08/15 17:26
Pier Capital, LLC Buys Everbridge Inc, RadNet Inc, Jamf Holding Corp, Sells Methode Electronics ...
GuruFocus News · 08/13 22:38
BRIEF-Cerus Corp Announces CMS Issuance Of P-Codes For Hospital Outpatient Billing Of Intercept-Based Therapeutic Products
reuters.com · 08/10 12:35
Cerus Reports US Centers For Medicare, Medicaid Services Granted Permanent Healthcare Common Procedure Coding System Level II Codes For Pathogen Reduced Crypoprecipitated Fibrinogen Complex
Cerus Corporation (NASDAQ:CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted permanent Healthcare Common Procedure Coding System (HCPCS) Level II codes for Pathogen Reduced
Benzinga · 08/10 12:35
Cerus Corporation Announces CMS Issuance of P-Codes for Hospital Outpatient Billing of INTERCEPT-Based Therapeutic Products
Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted permanent Healthcare Common Procedure Coding System (HCPCS) Level II codes for Pathogen Reduced Cryoprecipitated Fibrinogen Complex, o...
Business Wire · 08/10 12:30
Insider Trends: Insider at Cerus Converts Options in Mist of 90-Day Buying Trend
MT Newswires · 08/05 17:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CERS. Analyze the recent business situations of Cerus Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CERS stock price target is 9.00 with a high estimate of 10.00 and a low estimate of 7.50.
EPS
Institutional Holdings
Institutions: 241
Institutional Holdings: 163.96M
% Owned: 95.53%
Shares Outstanding: 171.63M
TypeInstitutionsShares
Increased
54
7.05M
New
25
2.97M
Decreased
53
7.36M
Sold Out
22
1.42M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Swisher
Chief Executive Officer/President/Director
William Greenman
Chief Financial Officer/Vice President - Finance
Kevin Green
Chief Operating Officer
Vivek Jayaraman
Senior Vice President
Carol Moore
Chief Scientific Officer
Laurence Corash
General Counsel
Chrystal Menard
Other
Richard Benjamin
Director
Ann Lucena
Independent Director
Eric Bjerkholt
Independent Director
Timothy Moore
Independent Director
Jami Nachtsheim
Independent Director
Gail Schulze
Independent Director
Frank Witney
No Data
About CERS
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Webull offers kinds of Cerus Corporation stock information, including NASDAQ:CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.